Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Undergraduate Student Research Awards (USRA)

University of Alberta

$6,000.00

Role of polysialic acid in inhibiting the anti-cancer immune response

EF 2024-25

Résumé
Cancer is the leading cause of death in Canada. A key feature of cancer progression is suppression of the anti-tumor immune response. We hypothesize that the immunomodulatory glycan polysialic acid (polySia), which is highly expressed on cell surfaces in many cancers, attenuates the anti-tumor immune response. PolySia is a long glycan that is normally found on just six cell-surface glycoproteins in the healthy human immune system, where it attenuates immune activation. PolySia is also expressed in many different types of cancer cells and the link between polySia and cancer progression is well established. However, the mechanism by which polySia enables cancer progression is unknown. We recently discovered that T cells express a polySia receptor which may attenuate their activation. T cells are critical components of the anti-cancer immune response but their function can become compromised in the tumor microenvironment. Cancer-expressed molecules that inhibit T cell activation and proliferation (i.e. immune checkpoints, like PD-L1) are associated with poorer outcomes in many different cancer types and provide targets for cancer immunotherapy. Hypersialylation of cancer cells and subsequent engagement of inhibitory sialic acid-receptors on immune cells has gained much attention recently for its potential as a new immune checkpoint axis. We hypothesize that engagement of the polySia receptor on T cells is a major mechanism by which cancer cells evade the immune response. To test this hypothesis, we first need to identify and characterize the polySia receptor. Mariam will 1) determine the phenotype of T cells that bind to polySia-proteins, and 2) identify the polySia receptor using proximity labeling.
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506719
Name
Adelaja Mariam
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of polysialic acid in inhibiting the anti-cancer immune response
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Alberta
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Anti-Tumor Immune Response; Polysialic Acid; Cancer; Polysia Reeceptor; T Cells
Abstract
Cancer is the leading cause of death in Canada. A key feature of cancer progression is suppression of the anti-tumor immune response. We hypothesize that the immunomodulatory glycan polysialic acid (polySia), which is highly expressed on cell surfaces in many cancers, attenuates the anti-tumor immune response. PolySia is a long glycan that is normally found on just six cell-surface glycoproteins in the healthy human immune system, where it attenuates immune activation. PolySia is also expressed in many different types of cancer cells and the link between polySia and cancer progression is well established. However, the mechanism by which polySia enables cancer progression is unknown. We recently discovered that T cells express a polySia receptor which may attenuate their activation. T cells are critical components of the anti-cancer immune response but their function can become compromised in the tumor microenvironment. Cancer-expressed molecules that inhibit T cell activation and proliferation (i.e. immune checkpoints, like PD-L1) are associated with poorer outcomes in many different cancer types and provide targets for cancer immunotherapy. Hypersialylation of cancer cells and subsequent engagement of inhibitory sialic acid-receptors on immune cells has gained much attention recently for its potential as a new immune checkpoint axis. We hypothesize that engagement of the polySia receptor on T cells is a major mechanism by which cancer cells evade the immune response. To test this hypothesis, we first need to identify and characterize the polySia receptor. Mariam will 1) determine the phenotype of T cells that bind to polySia-proteins, and 2) identify the polySia receptor using proximity labeling.
Competitiondate
202405
Approvedterm2
0 yr 6 mths
Pinamesdelim
Adelaja, Mariam
Approvedterm
0 an 6 mois
Cihrcontribution2
~ $6,000~ $0~